Proactive Investors - Run By Investors For Investors

Summit Therapeutics PLC's ridinilazole results continue to impress

Shares in Summit Therapeutics went higher as it revealed its new antibiotic for hospital superbug C.Diff could treat the disease and help stop it reoccurring.
Summit Therapeutics PLC's ridinilazole results continue to impress
Clostridium difficile, or C-diff, is a big threat in hospitals and care homes...

Shares in Summit Therapeutics PLC (NASDAQ: SMMT, LON: SUMM) went higher as it revealed its new antibiotic for hospital superbug C.Diff could treat the disease and help stop it reoccurring.

The further positive data comes from the CoDIFy Phase 2 clinical trial  and showed that ridinilazole can preserve the micobiome in the gut as it treats the condition, while the standard of care medicine - vancomycin - causes "substantial and long-lasting damage" on the microbiome, or the eco-system of the gut.

Clostridium difficile, or C-diff, is caused after damage to the microbiome but patients can get a double whammy, as using broad spectrum antibiotics can further damage the microbiome.

Glyn Edwards, chief executive of Summit, told investors: "These new results from the Phase 2 trial show ridinilazole preserves the patients' microbiome while simultaneously working to eradicate the C. difficile bacteria.

"The clinical data strongly suggest that ridinilazole treatment may be better able to protect against recurrent disease than the current standard of care.

"We believe this approach offers a clear advantage over conventional broad spectrum antibiotics currently used to treat CDI that cause substantial damage to the gut microbiome or approaches that aim to artificially re-establish a damaged gut microbiome following antibiotic treatment."

Summit reckons ridinilazole could become a single therapeutic approach capable of both treating the initial infection and reducing the high rates of recurrent disease.

Today's findings come after recently reported results from the Phase 2 CoDIFy trial that showed ridinilazole to be statistically superior to vancomycin in sustained clinical response.

C. diff is a serious threat in hospitals and care homes and there are between 450,000 and 700,000 cases in the US annually.

It is caused by an infection of the colon by the bacterium C. difficile, which produces toxins that causes inflammation, severe diarrhoea and in the most serious cases can be fatal.

Biopharma Summit, listed in London and New York, as well as C-diff, is focused on developing a treament for Duchenne muscular dystrophy.

Shares advanced in London 4.55% to 103.5p.

Why Invest In Summit Therapeutics PLC? Read More Here

Register here to be notified of future SUMM Company articles
View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

March 28 2017
2017 is going to be quite action packed we believe we have positioned the company for when RNA interference transforms from a technology to its promise of a new class of therapeutics - boss Ali Mortazavi.
cancer cells
February 10 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use